Abstract
Inflammation is a naturally occurring phenomenon in stroke and can be either a nonspecific reaction to a vascular insult or a primary component of the pathogenesis. The potential for the inflammation associated with connective tissue disorders to affect the cerebral or spinal circulation is well recognized. Perhaps the most common vasculitic process of the cerebral circulation encountered is temporal, i.e., giant cell arteritis. Determination of a primary component of vascular inflammation in the patient’s presentation can be quite challenging and remains extremely important as it will be vital in determining whether or not immunosuppressive therapy is indicated. Documentation of the vasculitic process in a timely fashion, the need for potent immunosuppressive therapy, as well as the choice and dosing of therapy, along with the duration, are important determinants of outcome in central nervous vasculitis. We hope to provide updated information toward these goals in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS. Lancet Neurol. 2011;10:561–72.
Birnbaum J, Hellman DB. Primary angiitis of the central nervous system. Arch Neurol. 2009;66:704–9.
Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system. Arthritis Rheum. 1997;40:1189–201.
Salvarani C, Brown Jr RD, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 2007;62:442–51.
Lie JT. Angiitis of the central nervous system. Curr Opin Rheumatol. 1991;3:36–45.
Salvarani C, Brown Jr RD, Calamia KT, et al. Primary CNS vasculitis with spinal cord involvement. Neurology. 2008;70:2394–400.
Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA. Idiopathic granulomatous angiitis of the central nervous system. Diagnostic challenges. Arch Neurol. 1993;50:925–30.
Parisi JE, Moore PM. The role of biopsy in vasculitis of the central nervous system. Semin Neurol. 1994;14:341–8.
Salvarani C, Brown Jr RD, Calamia KT, et al. Primary central nervous system vasculitis with prominent leptomeningeal enhancement: a subset with a benign outcome. Arthritis Rheum. 2008;58:595–603.
Salvarani C, Brown Jr RD, Christianson T, et al. An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis. Description of 163 patients. Medicine. 2015;21:1–15.
Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;4(371):50–7.
Broussalis E, Trinka E, Draus J, McCoy M, Killer M. Treatment strategies for vasculitis that affects the nervous system. Drug Discov Today. 2013;18:818–35.
Berlit P. Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord. 2010;3(3):29–42.
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.
Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.
Salvarani C, Brown Jr RD, Hunder GG. Adult primary central nervous system vasculitis. Lancet. 2012;380:767–77.
Call GK, Fleming MC, Sealfon S, Levine H, Kistler JP, Fisher CM. Reversible cerebral segmental vasoconstriction. Stroke. 1988;19:1159–70.
Sendara M, Chiras J, Cujas M, Lhermitte F. Isolated benign cerebral vasculitis or migrainous vasospasm? J Neurol Neurosurg Psychiatry. 1984;47:73–6.
Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible vasoconstriction syndromes. Ann Intern Med. 2007;146:34–44.
Ducros A, Bousser MG. Reversible cerebral vasoconstriction syndrome. Pract Neurol. 2009;9:256–67.
Wang SJ, Fuh JL, Wu JA, Chen SP, Lai TH. Bath-related thunderclap headache: a study of 21 consecutive patients. Cephalalgia. 2008;28:524–30.
Hu CM, Lin YJ, Fan YK, Chen SP, Lai TH. Isolated thunderclap headache during sex: orgasmic headache or reversible cerebral vasoconstriction syndrome? J Clin Neurosci. 2010;17:1349–51.
Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11:906–17.
Ducros A, Boukobaza M, Porcher R, Sarow M, Valade D, Bousser MG. Brain. 2007;130:3091–101.
Edlow JA, Caplan LR, O’Brien K, Tibbles CD. Diagnosis of acute neurlological emergencies in pregnant and post-partum women. Lancet Neurol. 2013;12:175–85.
Fugate JE, Ameriso SF, Ortiz G, et al. Variable presentations of postpartum angiopathy. Stroke. 2012;43:67–676.
Bartynski WS. Posterior reversible encephalopathic syndrome. Part 1: fundamental neuroimaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036–42.
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.
Ibrahim NMA, Badawy ME. MR imaging of posterior reversible encephalopathy syndrome associated with pregnancy. Egypt J Radiol Nucl Med. 2014;45:505–10.
Staykov D, Schwab S. Posterior reversible encephalopathy syndrome. J Intensive Care. 2012;27:11–24.
Jackson M, Lennox G, Jaspan T, Jefferson D. Migrainous angiitis precipitated by sex Headache and leading to watershed infarction. Cephalalgia. 1993;13:427–30.
Serdaru M, Chiras J, Cujas M, Lhermitte F. Isolated benign cerebral vasculitis or migrainous vasospasm? J Neurol Neurosurg Psychiatry. 1984;47:73–6.
Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Korosshetz WJ. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology. 2002;58:130–3.
Meschia JF, Malkoff MD, Biller J. Reversible segmental cerebral arterial vasospasm and cerebral infarction: possible association with excessive use of sumatriptan and Midrin. Arch Neurol. 1998;55:712–4.
Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features and risk factors. Stroke. 2010;41:2505–11.
Gonzalez-Gay MA, Vazquez-Rodriquez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–61.
Chacko JG, Chacko JA, Salter MW. Review of giant cell arteritis. Saudi J Ophthalmol. 2015;29:48–52.
Hunder GG, Da B, Michel BA, et al. The American College of Rheumatology 1990 criteria for classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.
Ly K-H, Regent MC, Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev. 2010;9:635–45.
Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–7.
Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731–40.
Gilden D, Nagel M. Varicella zoster virus in temporal arteries of patients with giant cell arteritis. J Infect Dis. 2015;212(Supple 1):S37–9.
Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;84:1948–55.
Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550–5.
Azhar SS, Tang RA, Dorotheo EU. Giant cell arteritis: diagnosing and treating inflammatory disorders in older adults. Geriatrics. 2005;60:26–30.
Guida A, Tufano A, Perna P, et al. The thromboembolic risk in Giant Cell Arteritis: a critical review of the literature. Int J Rheumatol. 2014;1:1–7.
Murchison AP, Gilbert ME, Bikyk JR, et al. Validity of the American College of Rheumatology Criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154:617–9.
Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of temporal arteritis. Semin Arthritis Rheum. 2012;41:866–71.
Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence and prognosis. Ann Rheum Dis. 2013;72:1989–94.
Saedon H, Saedon M, Goodyear S, Papettas T, Marshall C. Temporal artery biopsy for giant cell arteritis. Retrospective audit. JRSM Short Rep. 2012;3:73.
Kotter I, Henes JC, Wagner AD, Loock J, Gross WL. Does glucocorticosteroid-resistant Large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol. 2012;30(Suppl 70):S114–29.
Samson M, Puechal X, Devilliers H, et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev. 2014;13:197–205.
Younger DS. Vasculitis of the nervous system. Curr Opin Neurol. 2004;17:317–36.
Bougea A, Anagnostou E, Spandideas N, Triantafyllou N, Kararizou E. An Update of neurological manifestations of vasculitides and connective tissue diseases: a literature review. Einstein (Open Access). 2015;13:627–35.
Reichart MD, Bogousslavsky J, Janzer RC. Early lacunar strokes complicating polyarteritis nodosa: thrombotic microangiopathy. Neurology. 2000;54:883–9.
Vishwanath S, Relan M, Shen L, Ambrus Jr JL. Update on the use of biologics in vasculitides. Curr Pharm Biotechnol. 2014;15:558–62.
Ribi C, Cohen P, Pagnous C, et al. French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor prognosis factors. A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62:1186–1197.
Pagnoux C, Seror R, Henegar C, et al. for the French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database. Arthritis Rheum. 2010;62:616–626.
Semmo AN, Baumert TF, Kreisel W. Severe cerebral vasculitis as primary manifestation of hepatitis-B-associated polyarteritis nodosa. J Hepatol. 2002;37:414–6.
Salvarani C, Pipitone N, Hunder GG. Management of primary and secondary central nervous system vasculitis. Curr Opin Rheumatol. 2016;28:21–28.
Seror R, Mahr A, Ramanoelina J, et al. Central nervous system involvement in Wegener’s granulomatosis. Medicine. 2006;85:54–65.
Holle JU, Gross WL. Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol. 2011;23:7–11.
Fadil H, Gonzalez-Toledo E, Kelley RE, Henley J. Wegener’s granulomatosis with extension to the cavernous sinus. J La State Med Soc. 2007;159:212–4.
Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33:4–9.
Ku BD, Shin HY. Multiple bilateral non-hemorrhagic cerebral infarctions associated with microscopic polyangiitis. Clin Neurol Neurosurg. 2009;111:904–6.
Ozkul A, Tataroglu C, Kiylioglu N, Akoyi A, Tataroglu C. Microscopic polyangiitis presenting with medullary infarct. J Neurol Sci. 2011;300:173–5.
Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–100.
Wolf J, Bergner R, Mutallib S, Buggle F, Grau AJ. Neurological complications of Churg-Strauss syndrome-a prospective monocentric study. Eur J Neurol. 2010;17:582–8.
Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor- prognosis factors: a multicenter, prospective, randomized open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586–94.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med. 2010;363:221–32.
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. N Engl J Med. 2010;363:211–20.
Pagnoux C, Mahr A, Hamidou MA, et al. Azothrioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.
Kashiwagi T, Hayama N, Fujita E, et al. A case of (double) negative granulomatosis with polyangiitis (Wegener’s). CEN Case Rep. 2012;1:104–11.
Guellec D, Cornec-Le Gall E, Groh M, et al. ANCA-associated vasculitis in patients with primary Sjogren’s syndrome: detailed analysis of 7 new cases and systemic review of the literature. Autoimmun Rev. 2015;14:742–50.
Subramanyan R, Joy J, Balakrishman KG. Natural history of aortoarteritis (Takayasu’s disease). Circulation. 1989;80:429–37.
Wen D, Du X, Ma CS. Takayasu arteritis: diagnosis, treatment and prognosis. Int Rev Immunol. 2012;31:462–73.
Hirohata S. Central nervous system involvement in Behcet’s disease. Rinsho Shinkeigaku. 2001;41:1147–9.
Kidd D. Neurological complications of Behcet’s syndrome. Curr Neurol Neurosci Rep. 2012;12:675–9.
Saip S, Akman-Demir G, Siva A. Neuro-Behcet syndrome. Handb Clin Neurol. 2014;121:1703–23.
Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet’s disease. A follow-up for 4 years. Adv Exp Med Biol. 2003;528:575–8.
Espinoza GM, Prost A. Cogan’s syndrome and other ocular vasculitides. Curr Rheumatol Rep. 2015;17:24–7.
Angiletta D, Wiesel P, Marinazzo D, Bortone AS, Regina G. Endovascular treatment of multiple aneurysms complicating Cogan syndrome. Ann Vasc Surg. 2015;29:361–0.
Singer O. Cogan and Behcet syndromes. Rheum Dis Clin North Am. 2015;41:75–9.
Antonios N, Silliman S. Cogan syndrome: an analysis of reported neurological manifestations. Neurologist. 2012;18:55–63.
Dorr J, Krautwald S, Wildeman B, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9:307–16.
Kleffner I, Duning T, Lohmann H, et al. A brief review of Susac syndrome. J Neurol Sci. 2012;322:35–40.
Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemic vasculitis. Am J Med. 2015;128:950–5.
Ferr C, Sebastiani M, Colaci M, Poupak F, Piluso A, Antonelli A, Zignego AL. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific disorders, B-cell non-Hodgkins lymphoma, and cancer. World J Hepatol. 2015;7:327–43.
De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.
Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol. 2016;28:15–20.
Greenberg BM. The neurological manifestations of systemic lupus erythematosus. Neurologist. 2009;15:115–21.
Kelley RE, Stokes N, Reyes P, Harik S. Cerebral transmural angiitis and ruptured aneurysm. Arch Neurol. 1980;37:526–7.
Streifler JY, Molad Y. Connective tissue disorders: systemic lupus erythematosus, Sjogren’s syndrome and scleroderma. Handb Clin Neurol. 2014;119:463–73.
Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in Scleroderma: a systematic review. Semin Arthritis Rheum. 2013;43:335–47.
de Corte FC, Neves N. Cervical spine instability in rheumatoid arthritis. Eur J Orthop Surg Traumatol. 2014;24(Suppl 1):S83–91.
Nogueras C, Sala M, Sasal M, et al. Recurrent stroke as a manifestation of primary angiitis of the central nervous system in a patient infected with human immunodeficiency virus. Arch Neurol. 2002;59:468–73.
Garcia-Garcia JA, Macias J, Castellanos V, et al. Necrotizing granulomatous vasculitis in advanced HIV infection. J Infect. 2003;47:333–5.
Savige JA, Chang L, Horn S, Crowe SM. Antinuclear, anti-neutrophil cytoplasmic and anti- glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity. 1994;18:205–11.
McKelvie PA, Collins S, Thyagarajan D, Trost N, Sheorey H, Byrne E. Meningoencephalo-myelitis with vasculitis due to varicella zoster virus: a case report and review of the literature. Pathology. 2002;34:88–93.
Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of reactivation of varicella-zoster virus. N Engl J Med. 2000;342:635–45.
Grahn A, Studahl M. Varicella-zoster virus infections of the central nervous system- Prognosis, diagnostics and treatment. J Infect. 2015;71:281–93.
Russman AN, Lederman RJ, Calabrese LH, Embi PJ, Forghani B, Gilden DH. Multifocal Varicella-zoster virus vasculopathy without rash. Arch Neurol. 2003;60:1607–9.
Teng GG, Chatham WW. Vasculitis related to viral and other microbial agents. Best Pract Res Clin Rheumatol. 2015;29:226–43.
Smadja D, Mas JL, Fallet-Bianco C, Sicard D, de Recondo J, Rondot P. Intravascular lymphomatosis (neoplastic angioendotheliosis) of the central nervous system: case report and literature review. J Neurooncol. 1991;11:171–80.
Gaul C, Hannisch F, Neureiter D, Behrmann C, Neundorfer B, Winterhoffer M. Intravascular lymphomatosis mimicking disseminated encephalomyelitis and Encephalomyelopathy. Clin Neurol Neurosurg. 2006;108:486–9.
Berger JR, Jone R, Wilson D. Intravascular lymphomatosis presenting with sudden hearing loss. J Neurol Sci. 2005;232:105–9.
Vieren M, Sciot R, Robberecht W. Intravascular lymphomatosis of the brain: a diagnostic problem. Clin Neurol Neurosurg. 1999;101:33–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Kelley, R.E., El-Khoury, R., Kelley, B.P. (2017). Central Nervous System Vasculitis: Immunopathogenesis, Clinical Aspects, and Treatment Options. In: Minagar, A., Alexander, J. (eds) Inflammatory Disorders of the Nervous System. Current Clinical Neurology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-51220-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-51220-4_4
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-51218-1
Online ISBN: 978-3-319-51220-4
eBook Packages: MedicineMedicine (R0)